filings.toolsItem 1A. Risk Factors
2K characters. Original on sec.gov · Markdown
Item 1A. Risk Factors
Through the quarterly period covered by this report, there have been no material changes to the risk factors disclosed in Item 1A to Part I of Linde's Annual Report on Form 10-K for the year ended December 31, 2021.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities- Certain information regarding purchases made by or on behalf of the company or any affiliated purchaser (as defined in Rule 10b-18(a)(3) under the Securities Exchange Act of 1934, as amended) of its ordinary shares during the quarter ended September 30, 2022 is provided below:
| Period | Total Number of Shares Purchased (Thousands) | Average Price Paid Per Share | Total Numbers of Shares Purchased as Part of Publicly Announced Program (1,2) (Thousands) | Approximate Dollar Value of Shares that May Yet be Purchased Under the Program (1) (Millions) | |||||||||||||||||||
| July 2022 | 783 | $ | 278.82 | 783 | $ | 6,953 | |||||||||||||||||
| August 2022 | 1,462 | $ | 296.53 | 1,462 | $ | 6,520 | |||||||||||||||||
| September 2022 | 1,768 | $ | 278.56 | 1,768 | $ | 6,027 | |||||||||||||||||
| Third Quarter 2022 | 4,013 | $ | 285.16 | 4,013 | $ | 6,027 |
(1) On February 28, 2022, the company's board of directors approved the repurchase of $10.0 billion of its ordinary shares ("2022 program") which could take place from time to time on the open market (and could include the use of 10b5-1 trading plans), subject to market and business conditions. The 2022 program has a maximum repurchase amount of 15% of outstanding shares, began on March 1, 2022 and expires on July 31, 2024.
As of September 30, 2022, the company repurchased $4.0 billion of its ordinary shares pursuant to the 2022 program. As of September 30, 2022, $6.0 billion of share repurchases remain authorized under the 2022 program.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Previous: Item 1. Legal Proceedings · Next: Item 5. Other Information